<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4743">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 18, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04754698</url>
  </required_header>
  <id_info>
    <org_study_id>42566621.0.0000.0068</org_study_id>
    <nct_id>NCT04754698</nct_id>
  </id_info>
  <brief_title>CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS</brief_title>
  <acronym>CoronavRheum</acronym>
  <official_title>Immunogenicity and Safety of the CoronaVac Vacccine in Patients With Autoimmune Rheumatic Diseases and People Living With HIV/AIDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with chronic rheumatic diseases (such as systemic lupus erythematosus [SLE],&#xD;
      rheumatoid arthritis [RA], ankylosing spondylitis [AS], juvenile idiopathic arthritis [JIA],&#xD;
      poly/dermatomyositis [PM/DM], systemic sclerosis [SSc], systemic vasculitis, and primary&#xD;
      Sj√∂gren's syndrome [pSS]) are particularly susceptible to infectious diseases due to&#xD;
      autoimmune disorder itself and its treatment (immunosuppressive therapies). Similarly, people&#xD;
      living with HIV/AIDS (PLWHA) are predisposed to infections by different agents.&#xD;
&#xD;
      The current 2019 Coronavirus Disease Pandemic-19 (COVID-19), caused by the SARS-CoV-2 (severe&#xD;
      acute respiratory syndrome coronavirus 2) began in December 2019 in Wuhan, China, and quickly&#xD;
      became a global health and economic emergency by taking to an unprecedented burden on health&#xD;
      systems around the world.&#xD;
&#xD;
      However, SARS-Cov-2 infection raised particular concern in patients with autoimmune rheumatic&#xD;
      diseases (DRAI) since, due to chronic inflammatory immune dysregulation and the regular use&#xD;
      of immunosuppressive drugs, these patients are considered to be at high risk of contracting&#xD;
      SARS-CoV-2 and potentially evolving to a worse prognosis.&#xD;
&#xD;
      The overlap between the COVID-19 pandemic and the HIV/AIDS pandemic also poses an additional&#xD;
      challenge, as the impact of co-infection is not yet fully known. The response to vaccines for&#xD;
      other agents, however, has already been described as compromised in PLWHA.&#xD;
&#xD;
      Vaccination is the most effective preventive measure to control the spread of coronavirus and&#xD;
      to reduce associated complications. Usually, live or attenuated vaccines are not recommended&#xD;
      for patients with chronic rheumatic diseases using immunosuppressants. However, immunization&#xD;
      with inactivated agents is strongly indicated, resulting, in general, in good immunogenicity&#xD;
      and adequate vaccine safety, as well as without relevant deleterious effects on diseases.&#xD;
&#xD;
      Vaccine efficacy studies are needed to verify the immunogenicity of the vaccine against&#xD;
      COVID-19 in immunosuppressed patients with rheumatological disease and those with HIV-related&#xD;
      disease considering the risk of greater severity. In addition, it is important to assess the&#xD;
      safety of the vaccine in this population as well as the possibility of reactivating the&#xD;
      rheumatological disease itself.&#xD;
&#xD;
      The present study will evaluate the safety and immunogenicity of the CoronaVac (Coronavirus&#xD;
      vaccine, Sinovac Biotech Ltd.) in patients with rheumatic diseases and PLWHA&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A sample of 1254 patients with rheumatic diseases and 271 healthy controls matched for age&#xD;
      and sex was calculated as follows.&#xD;
&#xD;
      1.A) Evaluation of patients with SLE compared to a healthy control group matched for age and&#xD;
      sex. The investigators calculated 74 patients in each arm, which will be compared&#xD;
      independently to the healthy control group:&#xD;
&#xD;
        -  74 SLE patients treated with hydroxychloroquine alone;&#xD;
&#xD;
        -  74 SLE patients with mild immunosuppression (azathioprine or methotrexate and prednisone&#xD;
           &lt;10 mg/day);&#xD;
&#xD;
        -  74 patients with moderate to severe immunosuppression (mycophenolate mofetil or&#xD;
           cyclophosphamide and/or prednisone &gt;10 mg/day);&#xD;
&#xD;
        -  50 patients with belimumab (convenience sample). Total: 272 SLE patients and 74 healthy&#xD;
           controls.&#xD;
&#xD;
           1.B) Evaluation of RA patients compared to healthy controls matched for age and sex. The&#xD;
           investigators calculated 61 patients in each arm, which will be independently compared&#xD;
           to the control group:&#xD;
&#xD;
        -  61 RA patients only with conventional synthetic disease-modifying drugs (DMARDs);&#xD;
&#xD;
        -  61 RA patients with biological disease-modifying drugs (bDMARDs) with anti-TNF&#xD;
           (anti-tumor necrosis factor) action;&#xD;
&#xD;
        -  61 RA patients with bDMARDs with non-anti-TNF action and with impact on the production&#xD;
           of immunoglobulins (abatacept and rituximab);&#xD;
&#xD;
        -  61 RA patients with bDMARDs with anti-IL-6 (anti-interleukin-6) action (tocilizumab) and&#xD;
           synthetic drugs with anti-JAK (anti-janus kinase) action (tofacitinib).&#xD;
&#xD;
      Total: 244 RA patients vs. 61 healthy controls. 1.C) Evaluation of the interruption of the&#xD;
      use of methotrexate (MTX) for 4 weeks from the first dose of vaccination in RA patients.&#xD;
      Inclusion: patients using MTX in a stable dose for at least 4 weeks, prednisone maximum dose&#xD;
      of 7.5 mg/day, in association or not with other drugs, to be randomized in two arms: one that&#xD;
      keeps the therapy stable and the other which suspends MTX for 4 weeks from the first dose.&#xD;
      The investigators calculated 96 patients in each arm:&#xD;
&#xD;
        -  96 MTX patients who will not have their therapy changed;&#xD;
&#xD;
        -  96 MTX patients who will stop only MTX on the day of vaccination for 4 weekly&#xD;
           applications.&#xD;
&#xD;
      Total: 192 RA patients.&#xD;
&#xD;
      1.D) Evaluation of patients with AS/psoriatic arthritis compared to a healthy control group&#xD;
      matched for age and sex. The investigators calculated 136 patients in each arm, 136 with&#xD;
      synthetic DMARDs and 136 with bDMARDs, to be compared with 136 healthy controls matched for&#xD;
      age and sex.&#xD;
&#xD;
      Total: 272 patients with AS/psoriatic arthritis vs. 136 healthy controls.&#xD;
&#xD;
        1. E) A convenience sample of 250 (50 in each group) patients with other rare rheumatic&#xD;
           diseases (SSc, PM/DM, pSS, systemic vasculitis, and primary antiphospholipid antibody&#xD;
           syndrome) being followed up in Rheumatology Division (HCFMUSP) will be vaccinated and&#xD;
           matched using the pool of controls from the other samples.&#xD;
&#xD;
           Controls: 271 healthy controls matched for age and sex will be included according to the&#xD;
           need for controls for SLE (n = 74), RA (n = 61) and AS/psoriatic arthritis (n = 136)&#xD;
           will be selected to receive the vaccine at HCFMUSP.&#xD;
&#xD;
        2. PEOPLE LIVING WITH HIV/AIDS (PLWHA) The investigators considered the immunogenicity of&#xD;
           the vaccine for Yellow Fever as a parameter in a previous study carried out by our&#xD;
           group. The response found was p1 = 92% induction of neutralizing antibodies in PLWHA.&#xD;
           Considering the 1:1 ratio between vaccinated and controls, alpha error of 5% with 80%&#xD;
           power, the sample size will be 271 vaccinated in the PLWHA group and 271 in the control&#xD;
           group, with an effect size of 0.25.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Study consisting of 3 arms, all of which will receive CoronaVac: patients with rheumatic diseases, PLWHA, and healthy controls.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>50-56 days</time_frame>
    <description>Seroconversion rate of neutralizing antibodies to SARS-CoV-2</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">2067</enrollment>
  <condition>Rheumatic Disease</condition>
  <condition>HIV Infections</condition>
  <condition>AIDS</condition>
  <condition>Safety Issues</condition>
  <condition>Immunogenicity</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Patients with rhematic diseases</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>CoronaVac 2-dose schedule with 21-28-day interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with PLWHA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>CoronaVac 2-dose schedule with 21-28-day interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>CoronaVac 2-dose schedule with 21-28-day interval</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CoronaVac</intervention_name>
    <description>CoronaVac (Sinovac Biotech Ltd., Beijing, China)</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Patients with PLWHA</arm_group_label>
    <arm_group_label>Patients with rhematic diseases</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  RA patients according to the classification criteria of the European League Against&#xD;
             Rheumatism (EULAR)/American College of Rheumatology (ACR).&#xD;
&#xD;
          -  Patients with axial spondyloarthritis (ASAS criteria 2009) and psoriatic arthritis&#xD;
             (CASPAR 2012 criteria).&#xD;
&#xD;
          -  SLE patients according to the SLICC classification criteria.&#xD;
&#xD;
          -  SSc patients according to the ACR preliminary criteria.&#xD;
&#xD;
          -  patients with inflammatory myopathies according to the Bohan and Peter's criteria;&#xD;
&#xD;
          -  patients with primary vasculitis;&#xD;
&#xD;
          -  patients with pSS (2002 American-European Consensus group criteria and/or 2016&#xD;
             classification criteria of the EULAR/ACR;&#xD;
&#xD;
          -  patients with primary APS (primary antiphospholipid syndrome) (Sydney classification&#xD;
             criteria).&#xD;
&#xD;
          -  Patients with HIV-related illness.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of anaphylactic response to vaccine components.&#xD;
&#xD;
          -  Acute febrile illness.&#xD;
&#xD;
          -  Guillain-Barr√© syndrome, decompensated heart failure (class III or IV), demyelinating&#xD;
             disease.&#xD;
&#xD;
          -  History of live virus vaccine up to 4 weeks before, virus vaccine inactivated up to 2&#xD;
             weeks before.&#xD;
&#xD;
          -  History of having received blood products up to 6 months before the study.&#xD;
&#xD;
          -  Individuals who do not accept to participate in the study and/or whose guardians do&#xD;
             not agree to participate in the study.&#xD;
&#xD;
          -  Hospitalized patients.&#xD;
&#xD;
          -  Patients with severe conditions requiring hospitalization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kallas, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bonfa, MD, PhD</last_name>
    <phone>55 11 30617492</phone>
    <email>eloisa.bonfa@hc.fm.usp.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Sao Paulo General Hospital</name>
      <address>
        <city>S√£o Paulo</city>
        <state>SP</state>
        <zip>05403000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eloisa Bonfa</last_name>
      <phone>55 11 30617492</phone>
      <email>eloisa.bonfa@hc.fm.usp.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, Lightfoot RW Jr, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990 Aug;33(8):1129-34.</citation>
    <PMID>1975175</PMID>
  </reference>
  <reference>
    <citation>Avelino-Silva VI, Miyaji KT, Hunt PW, Huang Y, Simoes M, Lima SB, Freire MS, Caiaffa-Filho HH, Hong MA, Costa DA, Dias JZ, Cerqueira NB, Nishiya AS, Sabino EC, Sartori AM, Kallas EG. CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients. PLoS Negl Trop Dis. 2016 Dec 12;10(12):e0005219. doi: 10.1371/journal.pntd.0005219. eCollection 2016 Dec.</citation>
    <PMID>27941965</PMID>
  </reference>
  <reference>
    <citation>Avelino-Silva VI, Miyaji KT, Mathias A, Costa DA, de Carvalho Dias JZ, Lima SB, Simoes M, Freire MS, Caiaffa-Filho HH, Hong MA, Lopes MH, Sartori AM, Kallas EG. CD4/CD8 Ratio Predicts Yellow Fever Vaccine-Induced Antibody Titers in Virologically Suppressed HIV-Infected Patients. J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):189-95. doi: 10.1097/QAI.0000000000000845.</citation>
    <PMID>26361176</PMID>
  </reference>
  <reference>
    <citation>Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975 Feb 13;292(7):344-7. Review.</citation>
    <PMID>1090839</PMID>
  </reference>
  <reference>
    <citation>Brown LB, Spinelli MA, Gandhi M. The interplay between HIV and COVID-19: summary of the data and responses to date. Curr Opin HIV AIDS. 2021 Jan;16(1):63-73. doi: 10.1097/COH.0000000000000659. Review.</citation>
    <PMID>33186229</PMID>
  </reference>
  <reference>
    <citation>Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, Cats A, Dijkmans B, Olivieri I, Pasero G, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991 Oct;34(10):1218-27.</citation>
    <PMID>1930310</PMID>
  </reference>
  <reference>
    <citation>Emmi G, Bettiol A, Mattioli I, Silvestri E, Di Scala G, Urban ML, Vaglio A, Prisco D. SARS-CoV-2 infection among patients with systemic autoimmune diseases. Autoimmun Rev. 2020 Jul;19(7):102575. doi: 10.1016/j.autrev.2020.102575. Epub 2020 May 5. Review.</citation>
    <PMID>32376395</PMID>
  </reference>
  <reference>
    <citation>Fernandez-Ruiz R, Masson M, Kim MY, Myers B, Haberman RH, Castillo R, Scher JU, Guttmann A, Carlucci PM, Deonaraine KK, Golpanian M, Robins K, Chang M, Belmont HM, Buyon JP, Blazer AD, Saxena A, Izmirly PM; NYU WARCOV Investigators. Leveraging the United States Epicenter to Provide Insights on COVID-19 in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020 Dec;72(12):1971-1980. doi: 10.1002/art.41450. Epub 2020 Oct 28.</citation>
    <PMID>32715660</PMID>
  </reference>
  <reference>
    <citation>Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, Breedveld FC, D'Amelio R, Dougados M, Kapetanovic MC, van Laar JM, de Thurah A, Landew√© RB, Molto A, M√ºller-Ladner U, Schreiber K, Smolar L, Walker J, Warnatz K, Wulffraat NM, Elkayam O. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020 Jan;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882. Epub 2019 Aug 14.</citation>
    <PMID>31413005</PMID>
  </reference>
  <reference>
    <citation>Garc√≠a LF. Immune Response, Inflammation, and the Clinical Spectrum of COVID-19. Front Immunol. 2020 Jun 16;11:1441. doi: 10.3389/fimmu.2020.01441. eCollection 2020. Review.</citation>
    <PMID>32612615</PMID>
  </reference>
  <reference>
    <citation>Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, Izadi Z, Jacobsohn L, Katz P, Lawson-Tovey S, Mateus EF, Rush S, Schmajuk G, Simard J, Strangfeld A, Trupin L, Wysham KD, Bhana S, Costello W, Grainger R, Hausmann JS, Liew JW, Sirotich E, Sufka P, Wallace ZS, Yazdany J, Machado PM, Robinson PC; COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020 Jul;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871. Epub 2020 May 29.</citation>
    <PMID>32471903</PMID>
  </reference>
  <reference>
    <citation>Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, Calabrese LH, Fries JF, Lie JT, Lightfoot RW Jr, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum. 1990 Aug;33(8):1101-7.</citation>
    <PMID>2202308</PMID>
  </reference>
  <reference>
    <citation>Lightfoot RW Jr, Michel BA, Bloch DA, Hunder GG, Zvaifler NJ, McShane DJ, Arend WP, Calabrese LH, Leavitt RY, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum. 1990 Aug;33(8):1088-93.</citation>
    <PMID>1975174</PMID>
  </reference>
  <reference>
    <citation>Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P; International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004 Feb;31(2):390-2.</citation>
    <PMID>14760812</PMID>
  </reference>
  <reference>
    <citation>van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, M√ºller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013 Nov;65(11):2737-47. doi: 10.1002/art.38098. Epub 2013 Oct 3.</citation>
    <PMID>24122180</PMID>
  </reference>
  <reference>
    <citation>Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH; European Study Group on Classification Criteria for Sj√∂gren's Syndrome. Classification criteria for Sj√∂gren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002 Jun;61(6):554-8. Review.</citation>
    <PMID>12006334</PMID>
  </reference>
  <reference>
    <citation>Ye C, Cai S, Shen G, Guan H, Zhou L, Hu Y, Tu W, Chen Y, Yu Y, Wu X, Chen Y, Zhong J, Dong L. Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China. Ann Rheum Dis. 2020 Aug;79(8):1007-1013. doi: 10.1136/annrheumdis-2020-217627. Epub 2020 May 22.</citation>
    <PMID>32444415</PMID>
  </reference>
  <reference>
    <citation>Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, Chen X, Hu Y, Liu X, Jiang C, Li J, Yang M, Song Y, Wang X, Gao Q, Zhu F. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021 Feb;21(2):181-192. doi: 10.1016/S1473-3099(20)30843-4. Epub 2020 Nov 17.</citation>
    <PMID>33217362</PMID>
  </reference>
  <reference>
    <citation>Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306.</citation>
    <PMID>16420554</PMID>
  </reference>
  <reference>
    <citation>Rudwaleit M, Landew√© R, van der Heijde D, Listing J, Brandt J, Braun J, Burgos-Vargas R, Collantes-Estevez E, Davis J, Dijkmans B, Dougados M, Emery P, van der Horst-Bruinsma IE, Inman R, Khan MA, Leirisalo-Repo M, van der Linden S, Maksymowych WP, Mielants H, Olivieri I, Sturrock R, de Vlam K, Sieper J. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis. 2009 Jun;68(6):770-6. doi: 10.1136/ard.2009.108217. Epub 2009 Mar 17. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.</citation>
    <PMID>19297345</PMID>
  </reference>
  <reference>
    <citation>Rudwaleit M, van der Heijde D, Landew√© R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, S√∏rensen IJ, Ozgocmen S, Roussou E, Valle-O√±ate R, Weber U, Wei J, Sieper J. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009 Jun;68(6):777-83. doi: 10.1136/ard.2009.108233. Epub 2009 Mar 17. Erratum in: Ann Rheum Dis. 2019 Jun;78(6):e59.</citation>
    <PMID>19297344</PMID>
  </reference>
  <reference>
    <citation>Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, M√©nard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsk√Ω J, Wolfe F, Hawker G. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep;62(9):2569-81. doi: 10.1002/art.27584.</citation>
    <PMID>20872595</PMID>
  </reference>
  <reference>
    <citation>Petri M, Orbai AM, Alarc√≥n GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, S√°nchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin G Jr, Magder LS. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug;64(8):2677-86. doi: 10.1002/art.34473.</citation>
    <PMID>22553077</PMID>
  </reference>
  <reference>
    <citation>Tillett W, Costa L, Jadon D, Wallis D, Cavill C, McHugh J, Korendowych E, McHugh N. The ClASsification for Psoriatic ARthritis (CASPAR) criteria--a retrospective feasibility, sensitivity, and specificity study. J Rheumatol. 2012 Jan;39(1):154-6. doi: 10.3899/jrheum.110845. Epub 2011 Nov 15.</citation>
    <PMID>22089469</PMID>
  </reference>
  <reference>
    <citation>Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, Rasmussen A, Scofield H, Vitali C, Bowman SJ, Mariette X; International Sj√∂gren's Syndrome Criteria Working Group. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sj√∂gren's syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017 Jan;76(1):9-16. doi: 10.1136/annrheumdis-2016-210571. Epub 2016 Oct 26.</citation>
    <PMID>27789466</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CoronaVac</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Rheumatic disease</keyword>
  <keyword>Systemic lupus erythematosus</keyword>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>HIV</keyword>
  <keyword>AIDS</keyword>
  <keyword>Safety</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

